GlassScriptPhysician profile
John D Shugrue
NPI 1144467317
$1,253.17
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $474 · 2021: $18.77 · 2022: $22.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $589.22 | 2019-2021 | |
| Pacira Therapeutics, INC. | $117.98 | 2019-2020 | |
| Lilly USA, LLC | $77.97 | 2019-2022 | |
| Pfizer INC. | $74.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.82 | 2019-2020 | |
| Zyla Life Sciences, INC. | $41.73 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $38.54 | 2019 | |
| Aytu Biopharma, INC. | $35.05 | 2019 | |
| Genentech USA, INC. | $31.63 | 2019-2020 | |
| Bioventus LLC | $28.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.27 | 2019 | |
| Acera Surgical, INC. | $19.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.18 | 2020 | |
| Glaxosmithkline, LLC. | $17.95 | 2019 | |
| Shire North American Group INC | $17.79 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $16.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.92 | 2019 | |
| Circassia INC. | $15.45 | 2019 | |
| Adlon Therapeutics L.P. | $13.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shugrue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.